Clinical trial NCT00574470: Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
Official title: Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Graft vs Host Disease
Lead sponsor: University of Iowa
Sponsor class: OTHER
First posted: 2007-12-17
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see whether serious graft versus host disease which is not well controlled with steroid treatment can be controlled with therapy with both daclizumab and infliximab. We hypothesize that a combination of daclizumab and infliximab will more effectively treat graft versus host disease than therapy with a single drug. The study also looks at whether chronic graft versus host disease develops, and survival at 6 and 9 months post-treatment.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of steroid refractory aGVHD defined as no response to methylprednisolone at 2 mg/kg for 1 week or disease progression after 72 hours of methylprednisolone at this dose. Potential subject will have had no decrease in any GVHD organ staging as follows:

  * Skin rash, if present, does not decrease by one stage. This is based on the percent of the body involved with rash, plus presence of bullae and desquamation.
  * Gut GVHD, if present, does not decrease by one stage. This is based on volume of diarrhea, pain, and ileus.
  * Upper gastrointestinal GVHD, if present, does not resolve.
  * Liver GVHD, if present, does not decrease by one stage. This is based on total bilirubin level.
* Prior allogeneic hematopoietic stem cell transplantation using bone marrow, peripheral blood or umbilical cord cells. Recipients of standard as well as nonmyeloablative transplants are eligible.
* No previous immune suppressive therapy given for treatment of acute GVHD except for corticosteroids.
* Absolute neutrophil count greater than 0.5x106/L.
* Estimated creatinine clearance greater than 30 mL/minute.
* Written informed consent

Exclusion Criteria:

* Patient receiving either infliximab or daclizumab within seven days of study.
* Patient with uncontrolled infections will be excluded.
* Patients receiving other investigational agents for GVHD prophylaxis or treatment.
* Patients with congestive heart failure.
* Patients with history of intolerance/ hypersensitivity to daclizumab or infliximab.
* Age less than 18 years.
* Patients who are pregnant or at risk of pregnancy and unwilling to use acceptable birth control methods.
* Patients with an allergy to murine products.

Primary outcomes:
measure: Complete or partial response of GVHD to treatment according to standard staging/grading scale
timeFrame: 28 days
Secondary outcomes:
measure: incidence of chronic GVHD and overall survival
timeFrame: 9 months
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa Hospitals
state: Iowa
Study officials:
affiliation: University of Iowa Hospitals
name: Margarida Silverman, MD
role: PRINCIPAL_INVESTIGATOR
References: